Sermorelin Dosage: Approved Use vs Off-Label Protocols
Sermorelin dosing has been studied in the context of paediatric GH-deficiency and GH-axis diagnostic testing. Off-label adult protocols posted online (anti-aging, body composition) are not regulator-validated. This page does not publish a protocol; it explains the difference between the approved-use dose context and the off-label market.
Sermorelin dosing has been studied in paediatric GH-deficiency under specialist supervision and in GH-axis diagnostic testing. Off-label adult anti-aging or body-composition dosing protocols posted online are not regulator-validated and are not characterised by adequately controlled human trials in that population. Allmeds does not publish a protocol.
Key Takeaways
- Sermorelin has been studied in paediatric GH-deficiency and GH-axis diagnostic testing.
- Off-label adult anti-aging or body-composition dosing protocols posted online are not regulator-validated.
- Stimulating the GH/IGF-1 axis carries labelled risks (fluid retention, glucose intolerance, joint pain).
- Compounded sermorelin product quality is variable and not pharmaceutical-grade for off-label use.
- Allmeds does not publish dosing protocols for off-label peptide use.
Dosing in the approved use context
Sermorelin has been studied as a paediatric GH-deficiency treatment under specialist supervision and as a GH-axis diagnostic agent. The dosing in those contexts is determined and titrated by an endocrinology specialist based on individual clinical assessment. Allmeds does not publish those protocols here because they are not appropriate for self-administration.
Off-label adult protocols
Online protocols for anti-aging, body composition, or sleep are not regulator-validated. They are derived from anecdotal practice and informal extrapolation. The off-label adult population has not been characterised by adequately controlled trials of efficacy or safety in that context.
Risks of GH/IGF-1 axis stimulation
Stimulating the GH/IGF-1 axis carries recognised risks per the FDA label for the related drug tesamorelin (Egrifta): fluid retention, glucose intolerance and new-onset diabetes, peripheral oedema, joint pain, theoretical concern with active malignancy.
Check your medications before any change
Allmeds scans interactions across your full list. Free for individuals; team plans available.
Common Questions
Sermorelin doses studied in the approved-use contexts (paediatric GH-deficiency, diagnostic testing) are determined by an endocrinology specialist and individualised. Allmeds does not publish those values here because they are not appropriate for self-administration.
Various adult protocols circulate online. They are not regulator-validated and are not supported by adequately controlled trials in that population. They should not be used as a substitute for individualised specialist assessment.
Yes. The FDA label for the related drug tesamorelin (Egrifta) lists fluid retention, glucose intolerance, peripheral oedema, joint pain, hypersensitivity, and contraindication in active malignancy. Sermorelin acts on the same axis.
Compounded sermorelin sold for off-label anti-aging or body-composition use is not pharmaceutical-grade in the same sense as approved manufactured products. Discuss any planned use with a qualified clinician.
References
- U.S. Food & Drug Administration. Egrifta (tesamorelin) prescribing information. Source.
- U.S. Food & Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. Source.
- Therapeutic Goods Administration (Australia). Australian Register of Therapeutic Goods (ARTG). Source.